Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of livers from female mice treated for eight weeks with the glucagon analogue, NNC9204-0043, compared to female mice treated with PBS (control group)

ABSTRACT: RNA-seq of livers from female mice treated for eight weeks with the glucagon analogue, NNC9204-0043, compared to female mice treated with PBS (control group)

PROVIDER: PRJEB55275 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	ERR10038784_1.fastq.gz	Fastqsanger.gz
	ERR10038784_2.fastq.gz	Fastqsanger.gz
	ERR10038785_1.fastq.gz	Fastqsanger.gz
	ERR10038785_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 31

Similar Datasets

RNA-seq of livers from female mice treated for eight weeks with the glucagon analogue, NNC9204-0043, compared to female mice treated with PBS (control group)

Project description:Chronic glucagon receptor activation with a long-acting glucagon analogue increases amino acid catabolism, and to dissect the molecular mechanism underlying this effect, RNA sequencing of liver biopsies from female mice treated for eight weeks with GCGA or PBS were performed.

2022-10-11 | E-MTAB-12040 | biostudies-arrayexpress

RNA-seq of kidneys from mice treated for eight weeks with the glucagon analogue, NNC9204-0043, compared to mice treated with PBS

Project description:Chronic glucagon receptor activation induced by a long-acting glucagon analogue causes thickening of the parietal layer of Bowman’s capsule, causes mesangial area expansion, and formation of albuminuria. To dissect the molecular mechanism underlying these effects, RNA sequencing of kidney biopsies from female mice treated for eight weeks with either the long-acting glucagon analogue, NNC9204-0043, or PBS were performed

2023-12-01 | E-MTAB-12520 | biostudies-arrayexpress

RNA-seq of kidneys from mice treated for eight weeks with the glucagon receptor antibody, REGN1193, compared to mice treated with a control antibody, REGN1945.

Project description:Chronic glucagon receptor inhibition induced by a glucagon receptor antibody causes decrease in mesangial cell area and increases kidney weight. To dissect the molecular mechanism underlying these effects, RNA sequencing of kidney biopsies from female mice treated for eight weeks with the glucagon receptor antibody, REGN1193, or a control antibody, REGN1945, were performed.

2023-12-01 | E-MTAB-12518 | biostudies-arrayexpress

RNA-seq of livers from mice treated for eight weeks with the glucagon receptor antibody, REGN1193, compared to mice treated with a control antibody, REGN1945, (control group)

Project description:Chronic glucagon receptor inhibition with a glucagon receptor antibody decreases amino acid catabolism and ureagenesis, while increasing plasma triglyceride concentrations, plasma very-low density lipoprotein cholesterol concentrations, and liver triglyceride concentrations. To dissect the molecular mechanism underlying these effects, RNA sequencing of liver biopsies from female mice treated for eight weeks with the glucagon receptor antibody, REGN1193, or a control antibody, REGN1945, were performed.

2022-10-09 | E-MTAB-12048 | biostudies-arrayexpress

RNA-seq of kidneys from mice treated for eight weeks with the glucagon analogue, NNC9204-0043, compared to mice treated with PBS

Project description:RNA-seq of kidneys from mice treated for eight weeks with the glucagon analogue, NNC9204-0043, compared to mice treated with PBS

| PRJEB58999 | ENA

RNAseq liver Glucagon+T3

Project description:21 samples of liver RNA coming from mice treated with glucagon (Gluc), thyroid hormone (T3), both, or the conjugated compound (Cp). Each sample comes from a single mice.

2016-09-28 | GSE85793 | GEO

The transcriptome, enhancer landscape and GR binding profile in primary mouse hepatocytes treated with glucagon and corticosterone

Project description:The transcriptome, enhancer landscape and GR binding profile in primary mouse hepatocytes treated with glucagon and corticosterone

2022-05-09 | GSE189271 | GEO

Transcriptomics analysis of cells treated with Schizocommunin and its analogue

Project description:Transcriptomics analysis of cells treated with Schizocommunin and its analogue

| PRJNA532922 | ENA

Glucagon receptor signaling in GCGR KO mice

Project description:GCGR wt and ko mice Glucagon receptor signaling in GCGR KO mice: fig 2a in Solloway et al.

2015-06-02 | GSE68143 | GEO

Glucagon contributes to liver zonation in mice [Gcg infusion]

Project description:Liver zonation characterizes the separation of metabolic pathways along the lobules and is required for optimal function. Wnt/beta-catenin signaling controls metabolic zonation by activating genes in the perivenous hepatocytes, while suppressing genes in the periportal counterparts. We now demonstrate that glucagon opposes the actions of Wnt/beta-catenin signaling on gene expression and metabolic zonation pattern. The effects were more pronounced in the periportal hepatocytes where 28% of all genes were activated by glucagon and inhibited by Wnt/beta-catenin. The glucagon and Wnt/beta-catenin receptors and their signaling pathways are uniformly distributed in periportal and perivenous hepatocytes and the expression is not regulated by the opposing signal. Collectively, our results show that glucagon controls gene expression and metabolic zonation in the liver through a counter play with the Wnt/beta-catenin signaling pathway.

2018-03-01 | GSE110673 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data